Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50-Day Moving Average – Here’s Why

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.39 and traded as low as $3.97. Voyager Therapeutics shares last traded at $4.00, with a volume of 590,311 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on VYGR shares. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, HC Wainwright lowered their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.15.

Voyager Therapeutics Price Performance

The firm has a fifty day moving average of $4.39 and a 200 day moving average of $3.90. The stock has a market capitalization of $222.40 million, a price-to-earnings ratio of -1.85 and a beta of 1.23.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. The firm had revenue of $11.15 million during the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. Research analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of Voyager Therapeutics stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the sale, the chief financial officer owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of Montreal Can acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at about $36,000. Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at approximately $42,000. R Squared Ltd acquired a new position in Voyager Therapeutics in the second quarter valued at approximately $48,000. Los Angeles Capital Management LLC purchased a new position in Voyager Therapeutics in the second quarter worth approximately $50,000. Finally, Coldstream Capital Management Inc. acquired a new stake in Voyager Therapeutics during the third quarter worth $55,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.